*/
Misrepresentation – Negligent misrepresentation. The claimant invested £200,000 in a private company incorporated by the defendant to conduct further clinical trials of a new class of drug for the treatment hepatitis and a range of sexually transmitted diseases. She brought a claim, alleging that she had done so in reliance on negligent misstatement by the defendant. The Chancery Division held that the defendant was liable to the claimant for negligent misrepresentation by reason of the material omissions from a document issued by the directors of the company about the use of the investment proceeds. Damages were assessed in the sum of £200,000.
Misrepresentation – Negligent misrepresentation. The claimant invested £200,000 in a private company incorporated by the defendant to conduct further clinical trials of a new class of drug for the treatment hepatitis and a range of sexually transmitted diseases. She brought a claim, alleging that she had done so in reliance on negligent misstatement by the defendant. The Chancery Division held that the defendant was liable to the claimant for negligent misrepresentation by reason of the material omissions from a document issued by the directors of the company about the use of the investment proceeds. Damages were assessed in the sum of £200,000.
Now is the time to tackle inappropriate behaviour at the Bar as well as extend our reach and collaboration with organisations and individuals at home and abroad
A comparison – Dan Monaghan, Head of DWF Chambers, invites two viewpoints
And if not, why not? asks Louise Crush of Westgate Wealth Management
Marie Law, Head of Toxicology at AlphaBiolabs, discusses the many benefits of oral fluid drug testing for child welfare and protection matters
To mark International Women’s Day, Louise Crush of Westgate Wealth Management looks at how financial planning can help bridge the gap
Casey Randall of AlphaBiolabs answers some of the most common questions regarding relationship DNA testing for court
Maria Scotland and Niamh Wilkie report from the Bar Council’s 2024 visit to the United Arab Emirates exploring practice development opportunities for the England and Wales family Bar
Marking Neurodiversity Week 2025, an anonymous barrister shares the revelations and emotions from a mid-career diagnosis with a view to encouraging others to find out more
David Wurtzel analyses the outcome of the 2024 silk competition and how it compares with previous years, revealing some striking trends and home truths for the profession
Save for some high-flyers and those who can become commercial arbitrators, it is generally a question of all or nothing but that does not mean moving from hero to zero, says Andrew Hillier
